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ABSTRACT
Self-monitoring of blood glucose is now widely
recognized as efficacious to enhance and
facilitate diabetes management. More than just
a means of recording and storing data, some
blood glucose meters (BGMs) are now designed
with an embedded automated bolus calculator
(ABC) with the goal to propose patients
recommendations about insulin dosage. The
growing literature in this field tends to claim
that these new smart BGMs make patient’s life
easier and decision making safer. The main
purpose of this review is to verify whether BGMs
with a built-in ABC indeed improve the
willingness and the ability of insulin-treated
patients to make adequate therapeutic decisions
and positively impact the metabolic control and
the quality of life of ABC users. It appears that,
as long as the education provided by caregivers
remains a top priority, BGMs with a built-in
ABC (more than just electronic gadgets) can be
regarded as bringing real value to insulin-
treated patients with diabetes.
Keywords: Blood glucose meters; Bolus
calculator; Diabetes; Hypoglycemia; Self-
monitoring; Quality of life
INTRODUCTION
Evidence accumulated over past decades
convincingly demonstrates that adequate and
sustainable metabolic control in people with
diabetes results in better micro- and
macrovascular outcomes [1–6]. In addition,
when this control occurs early on, it may
confer a so-called metabolic memory [6].
However, it must be admitted that such
achievement remains elusive in a significant
proportion of patients, as more than 60% of
them are not reaching the advised glycated
hemoglobin (HbA1c) goal of \7% [7].
In addition to marked improvements in the
medical treatment of diabetes, increasing
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evidence indicates that regular assessment of
blood glucose (BG) levels may help insulin-
treated patients to achieve better glycemic
control. Self-monitoring of BG (SMBG)
contributes to better adjustment of therapies,
and helps to reach treat-to-target goals. More
importantly, SMBG can act as an educational
tool to support patients to better adhere to their
treatment [8–16]. SMBG may provide fruitful
feedback about how nutrition therapy, physical
activity, and medications influence BG levels
and alerts about hypo- and hyperglycemia [15].
However, some patients are reluctant to use
SMBG due to the pain associated with finger
sticks and the cost associated with SMBG
supplies. Additionally, some patients are
unable to interpret SMBG data and translate it
into appropriate therapeutic decisions [15].
One way to improve SMBG acceptance is to
provide therapy algorithms to support patients
[especially those treated by multiple daily
injection (MDI) or continuous subcutaneous
insulin infusion (CSII)] when interpreting their
values, and to react accordingly. Such tools are
already on the market.
METHODS
The question raised in this review is whether BG
meters (BGMs) with a built-in automated bolus
calculator (ABC) represent an added value in
patient performance and ability to make the
right therapeutic decisions, which may impact
both metabolic control and quality of life. A
literature search was carried out using Medline
and PubMed to select papers where an ABC was
used in addition to SMBG. The papers quoted in
this review were selected to bring insights into
specific questions concerning improved
capability of patients to make therapeutic
decisions, treatment satisfaction, improved
metabolic control and decreased glycemic
variability, and reduced fear and rate of
hypoglycemia.
Premeal Short-Acting Insulin Dose
Calculations
For SMBG to be considered useful, it should be
used regularly and correctly at the very least.
This goal is achieved when patients and
healthcare providers (HCPs) know how to
translate the data into appropriate insulin dose
adjustments [16]. To help patients make the
right decision, software has been developed to
calculate doses of short-acting insulin before
meals. This type of software has been available
in insulin pumps for over 10 years, but was only
recently integrated into BGMs and mobile
device applications [17]. MDI- and CSII-treated
patients are challenged with complex
mathematics before deciding on a premeal
short-acting insulin dose, at least three-times
daily. Patients are supposed to calculate their
insulin dose based on the following formula:





Insulin dosage is expressed in units (U). The
first part of the equation corresponds to a
division between the glucose load and the
insulin to glucose (or carbohydrate) ratio
(IGR). The glucose load, expressed in grams
(g), represents the amount of glucose intended
to be consumed, whereas IGR represents how
many grams of ingested glucose 1 U of insulin
covers. According to Walsh et al., IGR is
calculated as: 5.7 9 weight (kg)/total daily dose
(TDD) [18]. The correction dose, the second part
of the equation, is calculated by subtracting the
actual blood glucose level (aBGL) from the
target blood glucose level (tBGL), divided by
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the correction factor (CF), also referred to as the
insulin sensitivity factor (ISF) in other studies
[19–22]. CF represents how much 1 unit of
insulin lowers BG and is calculated as:
1,960 mg/dL/TDD, according to Walsh et al.
[18]. Insulin on board (IOB), the third part of
the equation, corresponds to how much insulin
remains theoretically active in the body from
the last dose. The IOB amount should be taken
into account and subtracted from the correction
dose. Of note, King recently proposed rounded
formulas for IGR (300/TDD), CF (1,500/TDD),
and total basal insulin dosage [TBD = 0.2 9
weight (kg)], which gives a slightly higher
estimate for bolus insulin and a lower estimate
for TBD [23]. The factors, IGR, CF, tBGL, and
IOB, should be continuously tailored by the
HCP for each patient.
One may easily understand that even well-
educated and motivated patients will inevitably
consider these calculations time consuming
with, on a long-term basis, the risk of mistakes
when dealing with so many variables clustered
in this equation. In reality, a significant
proportion of people with diabetes deal with
low literacy and low numeracy skills, which
often results in misinterpretation of the
recorded information, wrong therapeutic
decisions, and low therapeutic compliance,
thereby precluding correct metabolic control
[24–27]. Thus, one way diabetes device
manufacturers sought to facilitate the process
of therapeutic decisions was to incorporate an
ABC into insulin pumps and BGMs. BGMs with
built-in ABCs are mainly designed for MDI-
treated patients, as insulin pump users already
have calculators integrated into their pump.
These ‘‘smart’’ BGMs are also conceived to
provide an electronic log book and to store
information regarding insulin intake, food
consumption, physical activity, and health
information. They are sometimes engineered
to transmit data to web databases where they
are interpreted by specialized software systems
[28].
Do BGMs with Built-In ABCs Help Insulin-
Treated Patients to Make Appropriate
Therapeutic Decisions, While Improving
Treatment Satisfaction?
A recently published study reported
performances achieved by 205 insulin-treated
patients (47.6% with type 1 diabetes and 52.4%
with type 2 diabetes) who were asked, based on
scenarios of high or normal glucose test results
provided by control solutions, to manually
calculate mealtime doses of short-acting
insulin, followed by the same calculation
using a glucose meter with a built-in ABC [29].
Two cohorts of patients, either carbohydrate
counters (n = 101) who were using a
sophisticated formula, or noncarbohydrate
counters (n = 104) who were using a simplified
formula, were considered for the study. The
results showed that 63% of doses calculated
manually by the participants were erroneous,
whereas only 6% of incorrect responses were
recorded when calculations were performed
with an ABC. Eighty-three percent of subjects
felt confident about using the ABC and 87%
preferred the automated method to the manual
calculation. The study was not designed to
evaluate the direct impact of ABCs on
metabolic control, as the testing was based on
control solution values, not on actual blood
tests [29].
These results are in line with several previous
studies that showed only a small proportion of
people with diabetes able to adequately
calculate insulin doses, while taking into
account glucose load and BG levels. This may
explain the low level of treatment compliance
and therapeutic inertia over the long duration
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of diabetes [24, 30, 31]. These data are also
reminiscent of those from a 2008 study that
demonstrated a benefit of using an ABC in a
pediatric population of CSII-treated patients,
both in terms of personal satisfaction and
improved preprandial and 2-h postprandial BG
levels [32]. In one older study [31], an
improvement in treatment satisfaction,
adherence, and quality of life was shown in 83
adolescents using MDI or CSII. Another study
with 49 CSII-treated patients [33] reported
better postprandial BG excursions and good
confidence in the doses advised by the device
(Table 1 [29, 31–33]).
Do BGMs with Built-In ABCs Help
to Improve Metabolic Control
in Insulin-Treated Patients?
A recent study showed a significant
improvement in HbA1c values after a 6-month
follow-up in 40 consecutive MDI-treated type 1
diabetes patients using an ABC, compared
to standard methods (-0.85% vs. -0.007%;
P\0.05) [34]. This ABC-associated
improvement in metabolic control was further
confirmed in a recent Danish study that
reported, after 16 weeks, improved metabolic
control (HbA1c -0.7%) and treatment
satisfaction in a study group of MDI-treated
patients (called the CarbCountABC arm) that
received a 3-h educational program, flexible
intensive insulin therapy (FIIT) and an ABC as
compared to a group that only received FIIT
education (HbA1c -0.1%) [35]. The patients in
the CarbCountABC arm also experienced less
glycemic variability than those in the control
group and spent more time in the normal BG
range. They also needed less insulin due to more
appropriate dosing and less correction of
hyperglycemia. The results are in line with
those reported in a study of insulin guidance
software loaded into a personal data assistant.
In this group of 123 MDI-treated adult subjects
with type 1 diabetes, there was an improvement
in glycemic control, but no change in insulin
dose and no weight gain over a 12-month
period [36]. In addition, a higher proportion
of ABC users reached HbA1c values\7.5%, while
remaining within target limit BG levels
(70–150 mg/dL). Quite recently, a prospective
study performed over a period of 1 year where
30 type 1 diabetic patients were asked to use an
ABC, showed a significant decrease in diurnal
glucose variability (P\0.005), and improved
HbA1c (P = 0.007) and postprandial BG
(P\0.05) values. The frequency of
hypoglycemia was not increased [37].
In a small study (n = 18) published in 2008
comparing ABC users to nonusers, improved
metabolic control did not occur [34]. Although
mean postprandial BG levels in the ABC users
were significantly lowered compared to
nonusers, HbA1c values were not significantly
improved [38]. Noteworthy, this was an
observational study, not a randomized study.
Furthermore, the decision whether to use the
ABC or not was left to the patient’s discretion.
Two other quite recent studies in CSII-treated
young type 1 diabetic patients reached the same
conclusion. There was an improvement in 2-h
postprandial BG levels and glucose variability,
but no significant improvement of HbA1c values
[39, 40]. The discrepancies between these
studies can be understood considering
differences in study design and duration
(Table 2 [34–40]).
Are There Other Advantages to Using
BGMs with Built-In ABCs?
Another relevant advantage of using an ABC,
besides easier bolus calculation and the likely
improvement in metabolic control, or at least in
4 Diabetes Ther (2013) 4:1–11
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glucose variability, is the reduction in fear and
rate of hypoglycemia. This was shown in a
recent study that surveyed 1,412 MDI-treated
type 1 diabetes patients, of which 588 responded
positively [41]. The vast majority of them
(76.7%) claimed to use the ABC quite often or
Table 1 Impact of an ABC on patient satisfaction and quality of life





calculations of insulin doses
Evaluation of error frequency
when insulin dosages
calculated either manually or
with an ABC
Signiﬁcant reduction of errors when
doses calculated with an ABC
(P\0.001)
205 MDI-treated patients Improved conﬁdence and preference
of using an ABC (P\0.0001)
47.6% type 1 diabetes; 52.4% type
2 diabetes; 104 non-CC; 101 CC
Increased adherence may optimize the
use of meal-time insulin
Glaser
et al. [31]
12-month randomized control trial
comparing an IDC device to
conventional methods for insulin
doses
Impact of an ABC on metabolic
control
Higher rate of calculation errors with
conventional methods
83 MDI- or CSII-treated type 1
diabetes adolescents





satisfaction, adherence, and quality
of life among ABC users




2-week crossover study comparing
an ABC (Bolus Wizard) to
conventional methods for insulin
doses
Improvement of pre- and
postprandial glycemic control
Signiﬁcant reduction in pre- and 2-h
postprandial BG levels and in the
number of correction boluses
(P\0.05)
36 CSII-treated type 1 diabetes
adolescents




7-day crossover study comparing an




Less correction boluses to control
postprandial hyperglycemia when
using the ABC (P\0.05)
49 CSII-treated type 1 diabetes
subjects
Less supplemental glucose to raise low
BG levels when using the ABC
(P\0.05)
Decreased average deviation of 2-h
postprandial BG levels
ABC easy to use and conﬁdence in
advised insulin doses
ABC automated bolus calculator, BG blood glucose, CC carbohydrate counters, CSII continuous subcutaneous insulin
infusion, HbA1c glycated hemoglobin, IDC insulin dosage calculation, MDI multiple daily injection
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always. In 52% of respondents, the fear of
hypoglycemia was reduced and most of them
(78.8%) reported a high confidence in the insulin
dose calculation. In addition, 89.3% reported that
bolus calculation was made easy or very easy
when the bolus advisor was used. Although
Table 2 Impact of an ABC on HbA1c values
References Study design Objectives Results
Maurizi et al.
[34]
3- to 6-month randomized trial comparing patients
using an ABC to a control group
Effect of an ABC on
metabolic control at 3
and 6 months
At 3 months: nonsigniﬁcant improvement
in HbA1c levels (-0.61%)
40 consecutive adult type 1 diabetes patients At 6 months: signiﬁcant improvement in





16-week randomized, controlled, open-label, three-arm
parallel trial
Effect of FIIT and an
ABC on metabolic
control
Signiﬁcant improvement of HbA1c in the
arm of CarbCountABC (P\0.0001)
51 adult MDI-treated type 1 diabetes patients Effect of FIIT and an
ABC on treatment
satisfaction
Signiﬁcant improvement in treatment
satisfaction (DTSQs and DTSQc) in
the arm of CarbCountABC
(P\0.001)
Garg et al. [36] 1-year open-label, randomized, controlled trial Improvement of HbA1c
values
HbA1c improvement by[0.6% at
12 months (P\0.02)
123 adult type 1 diabetes patients randomized on a 1:1
basis to either an ABC or control group
Higher proportion of ABC users
achieving HbA1c\7.5% (P\0.01)
Within-target values higher among ABC
users
Without weight gain or changes in insulin
dosages
More severe hypoglycemia among ABC
users (P = 0.04)
Lepore et al.
[37]
1-year prospective observation study Improvement of HbA1c
values
Signiﬁcant improvement in HbA1c
(P\0.007)
30 CSII-treated type 1 diabetes patients already trained
to CH counting and ISF and invited to use an
insulin pump with an ABC
Signiﬁcant improvement of postprandial
BG levels (P\0.05)
Signiﬁcant improvement of daily glucose
variability (P\0.005)
Improved aptitude to calculate proper
dose of insulin bolus
No increased frequency of hypoglycemia
Klupa et al.
[38]
Observational study Improvement of HbA1c
values when using an
ABC (in an insulin
pump)
No signiﬁcant improvement in HbA1c
values




1-year multicenter study involving 40 CSII-treated
type 1 diabetes patients in three arms: control, CC,
CC plus ABC (in an insulin pump)
Improvement in HbA1c
levels and in meal-
related BG levels
No difference in HbA1c values
Decreased BG levels ﬂuctuations and
increase in postmeal BG levels within




3-month randomized, open-label study Changes in HbA1c,
postprandial glucose and
glucose variability
No change in HbA1c values
48 CSII-treated type 1 diabetic children randomly
allocated to a group using diabetics software, and a
control group using caloric tables and mental
calculations
Signiﬁcant decrease in 2-h postprandial
BG levels and in glucose variability
parameters (P\0.05)
ABC automated bolus calculator, BG blood glucose, CC carbohydrate counters, CSII continuous subcutaneous insulin infusion, DTSQc and DTSQs
diabetes treatment satisfaction questionnaires (change and status versions, respectively), FIIT ﬂexible intensive insulin therapy, HbA1c glycated
hemoglobin, IDC insulin dosage calculation, ISF insulin sensitivity factor, MDI multiple daily injection
6 Diabetes Ther (2013) 4:1–11
123
reduced fear of hypoglycemia is not a parameter
systematically reported in the literature, most of
the studies point out patient satisfaction and the
improved confidence in insulin dosage when
using an ABC. One may therefore presume that
the number of patients who skip insulin dosages
or commit calculation errors is likely to be lower
among those using an ABC compared to those
without. It is also more likely that ABC users are
more prone to follow insulin titration
instructions, which are key in maintaining
adequate metabolic control over time.
Even though data are contradictory about
hypoglycemic events, with at least one study
reporting more severe hypoglycemia among
ABC users [36], a recent study by Bergenstal
et al. [42], where an insulin support decision
algorithm was tested both in subjects with type
1 and type 2 diabetes, rather supports the idea
that the frequency of hypoglycemia is lower
among patients using an ABC. Thus, less
hypoglycemic episodes occurred in the groups
using the algorithm despite the higher rate of
insulin adjustment. Another important piece of
information brought forward by this paper is
related to the fact that besides subjects with
type 1 diabetes, two groups of subjects with type
2 diabetes (treated either with basal–bolus
therapy or twice-daily biphasic insulin) also
appeared to show benefit from the computer
decision system. This indicates that smart BGMs
should not be reserved only for subjects with
type 1 diabetes, but rather offered to all MDI-
treated patients, regardless of the type of
diabetes (Table 3 [41, 42]).
DISCUSSION
Although a consensus is emerging that SMBG
increases awareness of diabetes, as well as
patient’s empowerment and reassurance, there
are also papers reporting worsened quality of
life among patients using the SMBG method.
Of note, these studies were performed with type
2 diabetes patients who reported increased
anxiety and depression, and even obsessive
behaviour [43–47]. These feelings were often
associated with HCPs lack of interest to actively
check and use SMBG results that were otherwise
carefully collected by patients. This highlights
the pivotal educational role of HCPs about the
importance they bring to the interpretation of
SMBG results. From this view point, there is little
doubt that improved quality of life and patient
empowerment resulting from an increased
capability to use structured SMBG data and
translate it into appropriate therapeutic
decisions are two hallmarks of BGMs with built-
in ABCs. HCPs in combination with an ABC can
educate patients to interpret SMBG values and
make appropriate therapeutic decisions to meet
metabolic targets. Patients must deal with an
overload of variables such as BG levels, ICR,
glucose intake, target values, IOB, and physical
activity before making insulin dose decisions.
When correctly implemented and tailored to
each patient, the main advantage of an ABC is to
provide appropriate means to quickly make daily
decisions, which may contribute to a reduction
in hypoglycemic events and metabolic
instability. The literature reveals that BGMs
with built-in ABCs are used more often and
with increased confidence by patients, which
could be viewed as a real advantage, especially for
those who are confronted to low numeracy and/
or low literacy issues. One may reasonably
suppose that, because of improved metabolic
performances and quality of life, the increasing
use of BGMs with built-in ABCs may result in
reduced risks of long term micro- and
macrovascular complications. This medical
improvement may of course have positive
economic consequences because of long-term
Diabetes Ther (2013) 4:1–11 7
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improved HbA1c and a reduced rate of diabetes
complications [13].
To be efficacious, smart BGMs that are
expected to increase patient adherence to BG
monitoring, should be used by patients who
form a cohesive team with caregivers. It is of
course important that all patients understand
the relevance of SMBG and how to use it.
Noteworthy, this should be done while always
questioning the suggestions delivered by the
machine. For instance, a BGM cannot exempt
the patient to always predict changes in the
physical activity or diet habits in the hours
that follow the injection of insulin. Other
parameters, such as concurrent illnesses and
special medications (e.g., corticoids), must also
be taken into account. For all of these reasons,
ABC devices should be proposed to insulin-
treated patients who already have strong skills
to calculate bolus manually. This is the price to
pay for them to really understand and critically
review dosage recommendations proposed by
the software. According to the principle that
nothing is definitively fixed in the life of
patients and that everything may change
overtime, the customization of the device
must be continuously proposed and
supervised by HCPs who should keep
explaining to patients what to do with
recorded data. Thus, the key aspect for a
successful use of a smart BGM is education.
Regular assessments must be foreseen to make
sure that recommendations provided by the
system are done in a safe way and always in
close connection with the patient needs. As
long as the principle of ongoing education is
Table 3 Impact of an ABC on hypoglycemia
References Study design Objectives Results
Barnard
et al. [41]
Survey of 588 MDI-treated type 1
diabetic patients using an ABC
Reduced fear of
hypoglycemia
Mild or signiﬁcant reduction in fear of
hypoglycemia in 52% of respondents




improvement in the conﬁdence in
the insulin dose calculation in 78.8%
of respondents
Bolus calculation made easy or very




12-week intervention period (testing the
Diabetes Insulin Guidance system






Improvement in average BG levels
(P\0.03)
20 MDI-treated CC type 1 diabetes
patients, 20 MDI-treated non-CC type
2 diabetes patients, and six twice-daily




Improvement in mean HbA1c
(P\0.03)
Reduction by 25.2% of hypoglycemic
events (P = 0.02)
ABC automated bolus calculator, CC carbohydrate counters, BG blood glucose, HbA1c glycated hemoglobin, MDI multiple
daily injection
8 Diabetes Ther (2013) 4:1–11
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kept in mind, one may expect that using an
automated decision support algorithm will
bring a great relief to patients, especially to
those who are carbohydrate counters, because
they must deal with more difficult math than
those treated with fixed doses of insulin
eventually corrected by CF.
The reduced risk of hypoglycemia is
certainly another relevant advantage of BGMs
with built-in ABCs. The fear of hypoglycemia,
just as a low level of education, often precludes
the ability of patients to make changes and is a
source of therapeutic inertia. Hypoglycemia is
one of the main causes of alteration of the
patient’s quality of life. The ongoing technical
improvements and, for instance, the recent
progresses in telemedicine should make us
more confident in the ability of support
decision software to alert patients in real time
about hypoglycemia [48]. This is of course
crucial as, most of the time, actual systems do
not warn enough patients about hypoglycemia
and about the importance of managing it
before injecting the next dose of insulin. In
addition, they should also encourage patients
to inject insulin as soon as BG levels are getting
back to normal, a requirement that is often
neglected by patients when recovering from
hypoglycemia.
Decision softwares were initially designed to
help patients dealing with doses of short- or
rapid-acting insulin. Unfortunately, fasting
values, that are also known to influence HbA1c
values [49], are not yet included enough in the
calculation process. It should be easy for
manufacturers to propose ABC devices able to
counsel doses of long-acting insulin based on
few days of fasting BG levels. Positive or
negative trends in relation with chosen target
values would then be recorded and translated
into suggestions to increase or decrease the
dosages of basal insulin.
CONCLUSION
BGMs with an embarked ABC are effective
motivational tools that should be considered
more than just gadgets. They do bring a real
value in patient empowerment that is now
considered essential in diabetes management.
But this statement remains pertinent as long as
the principle of ongoing education and the
tight cohesion with the HCPs team are
preserved.
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